

## CONSOLIDATED CASH FLOW STATEMENT

January 1 to December 31, in million €	Note	2006	2005
<b>Cash provided by/used for operating activities</b>			
Net income		330	222
Minority interest	21	305	246
<b>Adjustments to reconcile net income to cash and cash equivalents provided by operating activities</b>			
Cash inflow from hedging		9	0
Depreciation and amortization	27	399	320
Loss on sale of investments		2	0
Change in deferred taxes	8	77	10
Loss on sale of fixed assets		14	7
<b>Change in assets and liabilities, net of amounts from businesses acquired or disposed of</b>			
Change in trade accounts receivable, net	11	-86	-42
Change in inventories	12	-49	-12
Change in prepaid expenses and other current and non-current assets	13	-101	-101
Change in accounts receivable from/payable to related parties		4	6
Change in trade accounts payable, accruals and other short-term and long-term liabilities		187	195
Change in accruals for income taxes		13	-71
Tax payments related to divestitures and acquisitions		-52	0
<b>Cash provided by operating activities</b>		<b>1,052</b>	<b>780</b>
<b>Cash provided by/used for investing activities</b>			
Purchase of property, plant and equipment		-589	-353
Proceeds from the sale of property, plant and equipment		18	22
Acquisitions and investments, net of cash acquired	2, 26	-3,657	-1,608
Proceeds from divestitures	2	438	2
<b>Cash used for investing activities</b>		<b>-3,790</b>	<b>-1,937</b>

January 1 to December 31, in million €	Note	2006	2005
<b>Cash provided by/used for financing activities</b>			
Proceeds from short-term borrowings	18	54	37
Repayments of short-term borrowings	18	-70	-70
Repayments of borrowings from related parties		-1	-4
Proceeds from long-term debt and liabilities from capital lease obligations	18	4,301	945
Repayments of long-term debt and liabilities from capital lease obligations	18	-1,828	-310
Changes of accounts receivable facility	18	137	-194
Proceeds from the exercise of stock options	28	75	90
Proceeds from the conversion of Fresenius Medical Care's preference shares into ordinary shares	1	258	0
Dividends paid		-171	-132
Proceeds from the issuance of bearer ordinary shares	22	0	438
Proceeds from the issuance of bearer preference shares	22	0	481
Payments of additional costs of capital increase	22	0	-22
Change in minority interest	21	1	-1
Exchange rate effect due to corporate financing		4	-2
<b>Cash provided by financing activities</b>		<b>2,760</b>	<b>1,256</b>
<b>Effect of exchange rate changes on cash and cash equivalents</b>		<b>-13</b>	<b>13</b>
<b>Net increase in cash and cash equivalents</b>		<b>9</b>	<b>112</b>
<b>Cash and cash equivalents at the beginning of the year</b>	10	<b>252</b>	<b>140</b>
<b>Cash and cash equivalents at the end of the year</b>	10	<b>261</b>	<b>252</b>

The following Notes are an integral part of the Consolidated Financial Statements.